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Summary At a median time of 20 months following high dose melphalan for myeloma, 29 patients relapsed
and were treated with induction chemotherapy to maximum response followed by a second course of high
dose melphalan. The majority (90%) of patients received 200 mg m2 with an autologous bone marrow
transplant. Sixteen (55%) patients achieved complete remission and 11 (38%) a partial response. The median
duration of remission was 17 (4-42) months. The median survival has not been reached, with 50% of patients
alive at 58 + months after presentation. The period of neutropenia was similar during both first and second
high dose procedures, but the duration of thrombocytopenia was longer in patients receiving melphalan for a
second time (median 22 (16-56) days and 41 (18-69) days respectively). There was one treatment-related
death due to thrombocytopenic haemorrhage.
Repeated administration of high dose melphalan is a feasible approach for patients with relapsed myeloma.
The use of high dose melphalan (HDM) as a single treatment
in patients with meyloma is associated with a high response
rate (McElwain & Powles, 1983; Selby et al., 1987). Complete
remission, defined by undetectable myeloma protein on
immunoelectrophoresis and normal bone marrow morpho-
logy (Gore et al., 1989) occurs in about 30% of patients with
a further 50% achieving a partial response (Selby et al.,
1987). The median duration of remission in responding
patients is 19 months with nearly all patients eventually
relapsing. In patients who have failed previous chemotherapy
with alkylating agents (usually low dose melphalan) the res-
ponse rate to HDM remains high at 66% but the duration of
remission is short, with a median of only 6 months and all
patients relapsing within a year (Selby et al., 1987). The
toxicity of this approach is predictable with a median period
of myelosuppression and thrombocytopenia of 28 and 24
days in previously untreated patients, and 42 and 37 days in
previously treated patients respectively (McElwain et al.,
1989).
The incorporation of an induction regimen to maximum
response prior to HDM has been used to try to improve the
complete remission rate and duration of remission. This
regimen consists of a 4 day continuous infusion of vincris-
tine, doxorubicin and methylprednisolone (VAMP) given
every 3 weeks, and has been used successfully in previously
treated and untreated patients (Forgeson et al., 1988; Gore et
al., 1989) to reduce tumour burden and the degree of marrow
infiltration. In those patients in whom the marrow infiltration
falls to less than 30% a higher dose ofmelphalan can then be
given together with an autologous bone marrow transplant
(ABMT), and this reduces the period of bone marrow sup-
pression (McElwain et al., 1989).
Since all patients eventually relapse following HDM fur-
ther treatment is always necessary. It is the practice in our
unit to treat relapsed patients with induction chemotherapy
to maximum response. Recently weekly cyclophosphoamide
has been added to VAMP in the hope of improving the
efficacy of the regimen. Bell et al. (1988) showed that the
clonogenic capacity of myeloma cells, assayed in vitro, from
patients receiving VAMP increased with successive cycles and
it was hoped that adding an alkylating agent would prevent
this. Fit patients who respond to VAMP ± cyclophospha-
mide then go on to receive a second treatment with HDM
and ABMT. We report our experience of this approach in
the management of relapsed myeloma.
Patients and methods
Patients
Between 1984 and 1989, 29 of 75 patients who had relapsed
following HDM received a second HDM. The decision not
to give a second course of HDM was based on the following
factors: (i) short duration of remission following first HDM
procedure (15), (ii) bone marrow infiltration too high to
consider autograft after induction chemotherapy prior to
second HDM (9), (iii) poor performance status (5), (iv) poor
renal function (2), (v) refused further HDM (2), (vi) subse-
quent treatment not at the Royal Marsden Hospital (3), (vii)
alternative high dose treatment given with busulphan (9) or
(viii) a syngeneic transplant with total body irradiation (1).
The median age of the patients at presentation was 43
(21-59) years, seven were female and 22 male. Patients were
classified according to their M protein - IgG kappa 12, IgG
lambda 7, IgA kappa 3, IgA lambda 4, IgD kappa 1, and
two non-secretors, and to the Durie-Salmon stage at presen-
tation - IA three; IIA one; IIIA 21 and IIIB four.
Previous treatment and response is shown in Table I. The
majority of patients (19/29) received 140 mg m-2 of mel-
phalan without an autologous bone marrow graft. Seven
patients received induction chemotherapy prior to HDM,
two achieving complete remission. Induction therapy con-
sisted of VAMP or VAD (dexamathasone replacing methyl-
prednisolone) in three and four patients respectively. No
patient received previous treatment with low dose alkylating
agents, but one patient had received high dose cyclophos-
phamide achieving a partial remission for 10 months prior to
the first HDM. The overall complete remission rate to this
first treatment was 62%. The median duration of remission
was 20 [range 6-64] months (21 [range 6-64] months for
those patients achieving a complete response and 16 [range
8-54] months for those patients achieving a partial res-
ponse).
Table I Response to first high dose melphalan
Induction chemotherapy No. of Response
+melphalan patients CR PR
140mgm-2 5 4 1
180-200 mg m-2 2 2 0
Melphalan alone
80-lOOmgm-2 3 1 2
140mgm-2 19 11 8
IC = induction chemotherapy; CR = complete response; PR = par-
tial response.
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Treatment
Induction chemotherapy
At relapse 28 of 29 patients received induction chemotherapy
with either VAMP (vincristine 0.4 mg and doxorubicin 9 mg
m 2 by continuous infusion daily for 4 days, together with
methylprednisolone 1.5 g either orally or by intravenous (i.v.)
bolus daily for 5 days) (seven patients) or VAMP with
weekly cyclophosphamide (cVAMP) 500 mg i.v. bolus pro-
viding the white blood cell count was greater than 2 x 109 1-'
and platelet count greater than 100 x 1091` (21 patients).
The chemotherapy was given via a central venous catheter
every 3 weeks.
During this treatment the following medication was given:
prophylactic antifungal agents (nystatin suspension 1 ml qds
and amphotericin lozenges 10 mg qds), oral ranitidine 150 mg
bd or cimetidine 800 mg od and more recently trimethoprin
80mg with sulphamethoxazole 40mg (two tablets bd alter-
nate days) as prophylaxis against bacterial infections.
Treatment with VAMP or cVAMP was continued until the
myeloma protein was undetectable by scanning densitometry
of serum proteins separated on cellulose acetate membrane
by electrophoresis and stained with Ponceau S (five patients)
or had reached a plateau (no change in myeloma protein
after two successive courses of induction therapy).
High dose melphalan
Approximately 6 weeks after the last course of induction
therapy fresh bone marrow was taken under general anaes-
thetic. Twenty-six patients then received HDM 200 mgm2
with ABMT, one each received 180 mg m-2, and 140 mg m-2
due to poor bone marrow harvests and one received 140 mg
m 2 without a graft because of persisting bone marrow
infiltration. Melphalan was given as an intravenous bolus via
a central venous catheter with a forced saline diuresis. All
patients received high dose methylprednisolone 1.5 g orally
or i.v. for 5 days with the marrow reinfusion. This regimen
has been described previously (Selby et al., 1987). Prophylac-
tic amphotericin lozenges and nystatin were given on admis-
sion together with cimetidine or ranitidine and a 7 day course
of allopurinol. Prophylactic antibiotics (gentamicin, piperacil-
lin and flucloxacillin) were started on day 5 post marrow
reinfusion and given until the neutrophil count was >0.5 x
109 I' with changes dependent on clinical or microbiological
evidence of resistant infection.
Toxicity
Toxicity was assessed on a daily basis according to WHO
criteria. Haematological toxicity data are available for all
patients. The white count and platelet count recovery curves
following the first and second HDM were calculated by the
Kaplan-Meier method (Kaplan & Meier, 1987) and the
differences assessed using the log-rank test (Peto et al., 1977).
Comparable gut toxicity data for both first and second high
dose treatments are available for 18 patients.
Response assessment andfollow-up
Response was assessed according to previously described
criteria: complete remission (CR) (all of the following)
(1) no paraprotein measurable by scanning densitometry of
serum proteins separated on cellulose acetate membrane
by electrophoresis and stained with Ponceau S;
(2) no detectable Bence-Jones proteinuria on electrophoresis
of neat urine stained with colloidal gold;
(3) 5% or fewer plasma cells of normal morphology on
bone marrow aspiration; and
(4) criteria 1-3 had to be fulfilled for at least 3 months.
Patients were regarded as having achieved partial remission
(PR) if there was a 50% decrease in measurable paraprotein
(IgG or IgA myeloma) or bone marrow infiltration (non-
secretory or Bence-Jones myeloma) which was sustained for a
month or more (Gore et al., 1989); for those patients who
received C.R. following the second HDM the duration of
response is dated from when this occurred.
Patients were reviewed 3 monthly in the clinic. Relapse was
defined as reappearance of a paraprotein/Bence-Jones pro-
teinuria and/or bone marrow infiltration with >5%
myeloma cells.
Results
Response to induction chemotherapy and HDM
The complete remission rate to VAMP or cVAMP was 18%
(five of 28) with an overall response rate of 54% (Table II).
A further 12 patients converted to complete remission
following HDM; four of these patients had not responded to
induction chemotherapy. The overall complete remission rate
was therefore 55% (16/29). Eight of the 11 patients who
achieved a partial response to HDM had not responded to
induction chemotherapy.
Duration of response (Figure 1)
At a median follow-up of 26 months (5-57 months) the
median duration of response was 17 (range 4-42+) months.
The median duration of response for those 16 patients who
achieved a complete remission was 19 (range 9-42+)
months. Eight of these 16 patients have not relapsed (at 11,
19, 19, 21, 23, 27, 35 and 42 months post HDM). This
compares with a relapse free interval of 14 (range 4-42)
months for those 11 patients who achieved a partial res-
ponse; four have no evidence of progressive disease at 4, 14,
14 and 30 months. One patient did not respond to either
induction chemotherapy or HDM but had stable disease for
33 months post HDM.
Eight patients had a longer disease-free interval following
the second HDM procedure compared to the first (Figure 1).
Follow-up
Twelve patients either in complete remission or stable partial
remission are on no treatment. Two patients who achieved a
partial remission are receiving maintenance a-Interferon as
part of a randomised trial comparing Interferon maintenance
with no further treatment.
Three patients have received a third high dose procedure
on relapse. One patient was given high dose melphalan and
has stable disease 12 months later and two patients received
high dose busulphan (16mgkg-' in divided doses over 4
days).
Of the remaining 13 patients, three had total body irradia-
tion and autologous bone marrow transplantation and died
of toxicity and ten were started on combination chemo-
therapy for progressive disease.
Survival
Five patients have died, one from toxicity as a result of
HDM. The median survival has not yet been reached, but
Table II Response to induction chemotherapy and second HDM
CR PR NC Total
Inductiona
VAMP 1 2 4 7
cVAMP 4 8 9 21
Total (%) 5 (18) 10 (36) 14 (46) 28
High dose melphalanb
Further responses post 12 8 0
IC
Total (%) 16 (55) 11(38) 1 (3) 29b
aOne patient did not receive induction chemotherapy. bOne toxic
death (this patient achieved a CR on induction chemotherapy). IC -
induction chemotherapy. NC - no change.HIGH DOSE MELPHALAN IN RELAPSED MYELOMA 985
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Figure 1 Comparison of duration of response following the first and second high dose melphalan.
following second HDM procedure.
50% of the patients are alive at 58 + months post diagnosis,
with a range of 23 + to 103 + months.
Toxicity
The major toxicity was myelosuppression. The majority of
patients did not have an ABMT at the time of the first
procedure whereas all but one patient did following the
second HDM. Furthermore, the dose of HDM was higher
for the second procedure. Thus the degree of myelosuppres-
sion was not strictly comparable. However the time taken for
the white cell count to recover was no different following the
second HDM compared with the first: median grade 4
(<1 x I09 1-1) toxicity 28 (range 20-45) days and 28 (range
16-48) days respectively. Conversely, the median time taken
to sustain a platelet count >25 x 109 -' was significantly
longer in patients receiving HDM for a second time (22
(range 16-56) vs 41 (range 18-69) days respectively),
(P<0.001). Alopecia and some degree of anorexia were
universal. A comparison of gut toxicity is shown in Figure 2.
Grade 3/4 stomatitis and diarrhoea occurred in two (11%)
and one (6%) patients following the first high dose procedure
and six (33%) and five (28%) following the second high dose
procedure respectively. The majority of patients had a fever
during the period of neutropenia but no patient died of
infective complications.
There were no deaths from the induction chemotherapy,
but one patient died during the second HDM procedure.
This patient had grade 4 thrombocytopenia from day 6
following bone marrow return. She had problems with pul-
monary infiltration due to infection and intrapulmonary
haemorrhage from day 19. Although this improved with
antibiotics and platelet support she developed a left hemi-
paresis and became increasingly unconscious on day 30. She
died several hours later. The cause of death was thought to
be due to an intracerebral haemorrhage. A postmortem was
refused. This was the patient who had received high dose
cyclophosphamide prior to her two HDM procedures.
Discussion
The prognosis for patients with myeloma has clearly im-
proved since the introduction of low dose alkylating agents
which give a median survival of 24-36 months (Durie &
Salmon, 1982; Sporn & McIntyre, 1986). For those patients
who have received HDM this has been extended to 5 years
(McElwain et al., 1989). However, this is a selected group of
patients and the use of HDM has not been evaluated in a
+ = patients still in remission
randomised trial against conventional treatment only. Mye-
loma, however, remains incurable even after HDM, and
further treatment is always necessary.
We have shown that it is possible to give a very high dose
of melphalan with or without autologous bone marrow rescue
on two occasions. Apart from prolonged thrombocytopenia,
resulting in the death of one patient, the haematological
toxicity experienced is similar for both groups, and no
patient died from infection or organ failure. This low mor-
tality compares very favourably to that which occurs when
patients with myeloma are given high dose chemotherapy
with an allogeneic bone marrow transplant. In a recent study
18/90 (20%) died before engraftment and the causes of death
at the time of the procedure, and subsequently, included
interstitial pneumonia (10%), acute graft vs host disease
(7%), bacterial and fungal infections (7%), haemorrhage
(6%), organ failure (4%) and adult respiratory distress synd-
rome (2%) (Gahrton et al., 1991). We now routinely check
the HLA status of the patient prior to the high dose proce-
dure so that HLA matched platelets can be given if no
increment occurs with unmatched platelets. The comparable
periods of neutropenia probably result from reinfusion of
autologous marrow with the higher dose of melphalan on the
second occasion.
Of interest is the relatively high complete remission rate
(18%) to induction chemotherapy prior to the second HDM
procedure. This compares with 6-28% in previously untreat-
ed patients using VAMP (Gore et al., 1989) or VAD (Sam-
son et al., 1989), and only 2% (1/45) in patients with
relapsed or refractory myeloma treated with VAMP (Forge-
son et al., 1988).
Following the entire VAMP HDM or cVAMP HDM a
total of 16 patients (55%) achieved a complete remission.
This is very simliar to the complete remission rate for
previously untreated patients (Gore et al., 1989). It is note-
worthy that this procedure is of value even in patients who
do not respond to induction therapy: four patients subse-
quently achieved a complete remission and eight a partial
response. However, this group has been specifically selected
because of previous response to high dose chemotherapy and
confirms our earlier report of high response rates in pre-
viously treated patients using cVAMP (Forgeson et al.,
1988).
Of further interest is the long duration of remission that
can occur following the second high dose procedure. This
compares favourably with the response duration achieved by
responding patients who received VAMP alone (Forgeson et
al., 1988). Patients treated with low dose melphalan before
HDM have a universally short remission-free period (Selby et
al., 1987) suggesting that a higher dose of melphalan does
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not overcome drug resistance. It appears that drug resistance
to repeated high dose melphalan does not occur so easily.
Treatment strategies to produce sustained remissions after
relapse are needed (McElwain et al., 1989) and a-Interferon
may have great promise in this context (Mandelli et al.,
1990). We are currently conducting a randomised trial in
previously untreated patients to determine if this approach is
of value in patients following HDM, since a-Interferon might
be of maximum benefit in patients with complete or good
partial remissions who exhibit the symptomatic and bio-
logical features of minimal residual disease: restoration of
normal immunoglobulin concentrations, bone healing and
normal performance status. Patients receiving HDM on two
occasions are in a position to receive maintenance a-
Interferon in second remission and can thus act as their own
control, providing the initial treatments are identical.
Until such time as it is possible to cure this disease repeat
high dose melphalan remains a useful therapeutic modality to
achieve second remissions. We advocate that for fit patients
under the age of 65 years bone marrow for cryopreservation
is taken following the first HDM procedure. On relapse the
patient receives induction chemotherapy followed by HDM
(200 mg m-' with the cryopreserved autograft) as part of a
planned programme of treatment.
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